Drug Type Small molecule drug |
Synonyms MY-008, MY008, MY008211A |
Target |
Action inhibitors |
Mechanism CFB inhibitors(Complement factor B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (United States), Priority Review (China) |
Molecular FormulaC27H32N2O4 |
InChIKeyYJJUEZFALZMWAP-URXFXBBRSA-N |
CAS Registry2797066-85-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemoglobinuria, Paroxysmal | NDA/BLA | China | 18 Oct 2025 | |
| Glomerulonephritis, IGA | Phase 2 | China | 30 Nov 2024 | |
| C3 glomerulopathy | IND Approval | China | 18 Dec 2023 | |
| Diabetic Nephropathies | IND Approval | China | 18 Dec 2023 | |
| Idiopathic Membranous Glomerulonephritis | IND Approval | China | 18 Dec 2023 | |
| Lupus Nephritis | IND Approval | China | 18 Dec 2023 |
Phase 2 | - | qywcwqsboe(sicbhaznmi) = n=15 of 34 patients tocwxlukjo (jywdwcsdkv ) View more | - | 08 Dec 2024 | |||





